Plans to sell a portion of investment securities and record 221,717 thousand yen as special profit. Sale period from September 1 to 18, 2026. Special profit to be recorded in the second quarter of the fiscal year ending March 2027. Possible revision to the current consolidated earnings forecast.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4584","jir_company_name":"Kidswell Biotech Corporation","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-18","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4584-20260918-01.pdf","jir_short_summary":"Plans to sell a portion of investment securities and record 221,717 thousand yen as special profit. Sale period from September 1 to 18, 2026. Special profit to be recorded in the second quarter of the fiscal year ending March 2027. Possible revision to the current consolidated earnings forecast.","jir_summary":"### Recording of special profit and details of the sale\nTo strengthen our financial position and improve asset efficiency, we plan to sell a portion of held investment securities and record the gains as special profit. The target is one listed security, with sale period from September 1 to 18, 2026, and expected gains of 221,717 thousand yen.\n\n### outlook and potential revision to earnings\nThe gains from the sale are expected to be recognized as special profit in the second quarter of the fiscal year ending March 2027. If necessary, the company will promptly disclose any revisions to the current consolidated earnings forecast.","jir_financial_highlights":"Investment securities sale proceeds: 221,717 \u5343\u5186 (Unknown)","jir_category":"","jir_hashtags":"#KidswellBioInvestorInfo, #SpecialProfitSale, #FinancialImprovement","jir_key_figures":"Investment securities sale proceeds: 221,717 \u5343\u5186\nSale period: 2026\u5e749\u67081\u65e5\uff5e18\u65e5\nTiming of recorded special profit: \u7b2c2\u56db\u534a\u671f 2027\u5e743\u6708\u671f\nTarget securities: 1 listed security","jir_meta_title":"\u3010Kidswell Biotech\u3011Notice of Recording of Special Profit\uff5cSeptember 2026","jir_meta_description":"Kidswell Biotech plans to record 221,717 thousand yen as special profit from the sale of investment securities. Sale period is in September 2026, with possible revision to the current earnings forecast. Please see the notice for details.","jir_og_title":"\u3010Kidswell Biotech\u3011Notice of Recording of Special Profit","jir_og_description":"Recording investment securities sale gains as special profit. Sale period in September 2026, impact on the second quarter of the fiscal year ending March 2027. Also mentions potential revisions to this year's earnings forecast.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58797,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-115413","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n